[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia---bacterial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia---bacterial":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,77,106,134,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641723","combination-vs-monotherapy-for-stenotrophomonas-maltophilia-infections-100641723",false,"NCT07593547","Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections","Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections: A Multicentre Study Using Target Trial Emulation","EMULATE-Sm","Inclusion Criteria:\n\n* Adult patients\n* S. maltophilia infections\n* Different episodes if a new infection ocurred \\> 30 days since the index episode\n\nExclusion Criteria:\n\n* isolates obtained from patients outside of hospital admission\n* microbiological or clinical colonization\n* hospitalizations shorter than 72 hours since the time zero\n* patients who died in the first 72 hours since the time zero or who were in imminent risk of death\n* polymicrobial infections\n* receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours\n* absence of data outcomes","ALL","18 Years",{"count":20,"type":21},790,"ESTIMATED","60 Days","OBSERVATIONAL","The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is:\n\n• Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections?\n\nResearchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.",[26,27,28],"Bloodstream Infection","Pneumonia - Bacterial","S Maltophilia Infections",[30,31,32,33],"S. maltophilia","Infection","Mortality","Combined therapy","RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-03-06",{"date":42,"type":21},"2026-12-31",{"name":44,"class":45},"Instituto de Investigación Sanitaria Gregorio Marañón","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100630830","phase-1-mp101-in-adults-with-acute-pseudomonas-aeruginosa-pneumonia-100630830","NCT07492771","MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of MP101 in Adult Patients With Acute Pseudomonas Aeruginosa Pneumonia","MP101-1001","Inclusion Criteria:\n\n* Subjects aged 19 years or older.\n* Clinical diagnosis of acute pneumonia with radiologic evidence of pulmonary infiltrates.\n* Confirmed Pseudomonas aeruginosa (PA) infection via valid respiratory specimens.\n* PA isolate demonstrates susceptibility to MP101 and non-susceptibility to current antibiotic therapy.\n* Adequate organ function as defined by hematological, hepatic, and renal laboratory parameters .\n\nExclusion Criteria:\n\n* Persistent septic shock or hemodynamically unstable condition.\n* Active pulmonary tuberculosis or suspected non-bacterial pneumonia.\n* Significant pleural effusion or lung abscess requiring therapeutic drainage.\n* Clinically significant cardiovascular, hepatic, or renal impairment .\n* Immunocompromised status or history of hematological malignancies.\n* Known hypersensitivity to bacteriophages, study components, or concomitant antibiotics.\n* Participation in another clinical trial within 30 days prior to screening.\n* Any medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study.","19 Years",{"count":57,"type":21},18,"INTERVENTIONAL",[60],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia. The study will also assess the pharmacokinetic and pharmacodynamic characteristics of MP101 and its antibacterial activity, including changes in P. aeruginosa burden in sputum and changes in susceptibility to MP101 and concomitant antibiotics.",[27,63],"Pseudomonas Aeruginosa Infection",[65],"Acute Pseudomonas Aeruginosa Pneumonia","NOT_YET_RECRUITING","2026-05-22",{"date":69,"type":38},"2026-05-26",{"date":71,"type":21},"2026-06-15",{"date":73,"type":21},"2026-12",{"name":75,"class":76},"MicrobiotiX Co., Ltd","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100637241","impact-of-biofire-filmarray-pneumonia-panel-vs-routine-diagnostics-on-antimicrobial-outcomes-door-mat-100637241","NCT07585604","Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)","A Randomized Multicenter Clinical Trial Comparing BIOFIRE® FILMARRAY® Pneumonia (PN) Panels Versus Routine Diagnostic Methods in Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) in Hospitalized Patients With Lower Respiratory Tract Infections.","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinical diagnosis of hospital-acquired pneumonia or clinically relevant tracheobronchitis requiring antimicrobial treatment, with or without mechanical ventilation.\n* No respiratory cultures collected in the last 72 hours (except for the culture that will potentially be evaluated in the study-trigger for inclusion).\n* Agreement from the patient or legal representative to sign the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Inadequate respiratory samples according to laboratory cutoffs for squamous epithelial cells and polymorphonuclear leukocytes (sputum or endotracheal aspirate).\n* Incarcerated populations.\n* Pregnant women.",{"count":85,"type":21},150,[87],"NA","Multidrug-resistant bacterial infections are a growing global health concern. Hospital-acquired pneumonia is one of the most common infections occurring during hospitalization and can be associated with high mortality, reaching up to 50% in severe cases. One of the main reasons for poor outcomes is the delay in starting the most appropriate antibiotic treatment.\n\nStandard laboratory methods used to identify the bacteria and determine which antibiotics are effective usually take between 48 and 96 hours to provide results. During this time, patients often receive broad-spectrum antibiotics, which may not be optimal and can contribute to antimicrobial resistance.\n\nRapid diagnostic tests, such as the BIOFIRE® FILMARRAY® Pneumonia Panel, can detect multiple bacteria and important resistance markers directly from respiratory samples in about one hour. These tests are already approved for use in Brazil and are easy to perform. Previous studies in patients with community-acquired pneumonia have shown that these rapid tests can help doctors choose more appropriate antibiotics earlier and may improve patient outcomes.\n\nHowever, their benefit has not been well studied in patients with hospital-acquired pneumonia, especially in settings where multidrug-resistant bacteria are common. In these situations, early and appropriate adjustment of antibiotic therapy is particularly important for improving outcomes and ensuring the responsible use of advanced antibiotics.\n\nThis study aims to compare the use of rapid diagnostic panels with standard laboratory methods in hospitalized patients with suspected pneumonia. The main focus is to evaluate how quickly and how appropriately antibiotic treatment can be adjusted after sample collection, using a structured scoring system, the Desirability of Outcome Ranking for the Management of Antimicrobial Therapy(DOOR-MAT), as well as to assess clinical outcomes.\n\nThe results of this study may help determine whether rapid diagnostic testing improves patient care in real-world hospital settings. The findings could support decision-making within the Brazilian Unified Health System (SUS) regarding the adoption of this technology, and may also contribute to future analyses of its cost-effectiveness.",[27],[91,92,93,94,95,96],"BIOFIRE® FILMARRAY®","Hospital-acquired pneumonia","Ventilator-associated pneumonia","DOOR-MAT","Antimicrobial resistance","Cost-effectiveness","2026-05-08",{"date":99,"type":38},"2026-05-14",{"date":101,"type":21},"2026-05-02",{"date":103,"type":21},"2027-06-02",{"name":105,"class":45},"Hospital de Clinicas de Porto Alegre",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100606872","urine-pneumococcal-antigen-project-100606872","NCT07181200","Urine Pneumococcal Antigen Project","Accelerating the Development of an Extended-specificity Multiplex Urine Immunoassay for the Diagnosis and Serotyping of Pneumococcal Pneumonia in High Carriage and Disease Burden Settings Like Malawi","UPAP","Inclusion criteria for healthy children in the community\n\n• Child aged between12-24 months.\n\nExclusion criteria for healthy children in the community\n\n* Presence of any of the following symptoms: fever, cough, difficulty in breathing or fast breathing.\n* Currently taking long-term antibiotic prophylaxis, TB treatment or immunosuppressive medications.\n* Diagnosis of an immunosuppressive illness, including HIV infection.\n* Hospital admission within the past six months.\n\nInclusion criteria for children with pneumonia in the community\n\n* Child aged between12-24 months.\n* Presence of all of the following symptoms: fever, cough, difficulty in breathing and fast breathing.\n* Participant has been prescribed antibiotics for treatment of a lower respiratory tract infection on this presentation.\n\nExclusion criteria for children with pneumonia in the community\n\n* Severe anaemia, with a recorded haemoglobin level \\\u003C 70 grams per Litre.\n* Currently taking long-term antibiotic prophylaxis, TB treatment or immunosuppressive medications.\n* Diagnosis of an immunosuppressive illness, including HIV infection.\n* Hospital admission within the past six months.\n\nInclusion criteria for children hospitalised with pneumonia\n\n* Child aged between 12-24 months.\n* Presence of all of the following symptoms: fever, cough, difficulty in breathing and fast breathing.\n* Participant has been prescribed antibiotics for treatment of a lower respiratory tract infection on this presentation.\n\nExclusion criteria for children hospitalised with pneumonia\n\n* Severe anaemia, with a recorded haemoglobin level \\\u003C 70 grams per Litre.\n* Currently taking long-term antibiotic prophylaxis, TB treatment or immunosuppressive medications.\n* Diagnosis of an immunosuppressive illness, including HIV infection.\n* Hospital admission within the past six months.\n\nInclusion criteria for children re-hospitalised with pneumonia\n\n* Child aged between12-24 months.\n* Presence of all of the following symptoms: fever, cough, difficulty in breathing and fast breathing.\n* Participant has been prescribed antibiotics for treatment of a lower respiratory tract infection on this presentation.\n* Hospital admission to ANY hospital with a lower respiratory tract infection within the past 3 months.\n\nExclusion criteria for children re-hospitalised with pneumonia\n\n* Severe anaemia, with a recorded haemoglobin level \\\u003C 70 grams per Litre.\n* Currently taking long-term antibiotic prophylaxis, TB treatment or immunosuppressive medications.\n* Diagnosis of an immunosuppressive illness, including HIV infection.",true,"12 Months","24 Months",{"count":118,"type":21},350,"Background:Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa. Accurate diagnosis remains challenging due to the need for invasive procedures to obtain samples for culture-based diagnostic tests, which are not very sensitive for detecting S.pneumoniae, particularly after antibiotic use.\n\nSerotype-specific urinary antigen detection (ssUAD) assays are a promising, non-invasive alternative for the surveillance and diagnosis of pneumococcal disease. Importantly, they can identify different serotypes of S.pneumoniae, which is crucial for monitoring vaccine impact. However, the ability of the ssUAD to identify invasive disease due to S.pneumoniae has not been studied in children in sub-Saharan Africa, where high rates of asymptomatic carriage may affect diagnostic accuracy.\n\nAim:\n\nThe overall aim of this study is to evaluate the performance of the ssUAD test to detect pneumococcal carriage, and distinguish it from invasive disease, among children under five years old in Blantyre, Malawi.\n\nMethods:This study will test 350 existing urine samples that have already been collected from children as part of the NP Resistome study (Protocol V 5.0, LSTM reference 24-076), including healthy children in the community, children with pneumonia in the community, and children hospitalised with pneumonia. Participants of the NP Resistome study will be recruited from Ndirande Health Centre (NHC), Gateway Primary Care Centre (GPCC) and Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi. Aliquots from each urine sample will be tested using the ssUAD in the UK, as the assay is not currently available in Malawi. Urinary detection of pneumococcal serotypes will be compared with both culture-based and metagenomic sequencing results from nasopharyngeal swab samples taken as part of the main study.",[121,27],"Pneumonia",[123,124],"Urinary pneumococcal antigen","Serotype-specific urinary antigen detection","2025-09-12",{"date":127,"type":38},"2025-09-18",{"date":129,"type":21},"2025-10",{"date":131,"type":21},"2027-08",{"name":133,"class":45},"Liverpool School of Tropical Medicine",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":141,"enrollmentInfo":142,"targetDuration":144,"studyType":23,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":46},"100599584","different-methods-of-aerosolized-polymyxin-b-inhalation-for-treating-carbapenem-resistant-gram-negative-bacterial-pneumonia-100599584","NCT07086391","Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.","A Prospective Clinical Study on Different Methods of Aerosolized Polymyxin B Inhalation for the Treatment of Carbapenem-Resistant Gram-Negative Bacterial Pneumonia","Inclusion Criteria:\n\n* Pneumonia diagnosed per Chinese Thoracic Society criteria (radiographic + clinical evidence).\n* Sputum culture-confirmed carbapenem-resistant Gram-negative bacteria susceptible to polymyxin B.\n* ≥3 days of aerosolized polymyxin B therapy.\n* Mechanically ventilated with an artificial airway.\n\nExclusion Criteria:\n\n* Polymyxin B aerosol use planned for \\\u003C3 days.\n* Terminal status (life expectancy \\\u003C48h).\n* Severe liver\u002Fkidney dysfunction (ALT\u002FAST \\>5× ULN; eGFR \\\u003C30 mL\u002Fmin).\n* No informed consent.","90 Years",{"count":143,"type":21},144,"28 Days","Study Design:\n\nA randomized, open-label, parallel-group clinical trial comparing the efficacy and safety of jet nebulization versus vibrating mesh nebulization of sulfate polymyxin B in mechanically ventilated patients with carbapenem-resistant Gram-negative bacterial pneumonia.\n\nParticipants:\n\n144 patients (72 per group) will be enrolled from December 2023 to December 2025.\n\nInterventions:\n\nGroup A: 25mg polymyxin B + 5ml sterile water via jet nebulizer (respirator-assisted).\n\nGroup B: 25mg polymyxin B + 5ml sterile water via vibrating mesh nebulizer (respirator-assisted).\n\nBoth groups receive additional intravenous polymyxin B (2.0mg\u002Fkg loading dose, followed by 1.25mg\u002Fkg every 12h) starting 12h after nebulization.\n\nTreatment duration: 14 days.\n\nKey Procedures:\n\nNebulization parameters: Fixed ventilator settings (SIMV+PSV mode, tidal volume 8ml\u002Fkg, PEEP 6cmH₂O).\n\nBronchoalveolar lavage (BAL) and blood sampling:\n\nBAL fluid (BALF) and blood collected pre-nebulization (baseline), 1h post-nebulization, and at steady-state (days 3-7).\n\nBALF analyzed for polymyxin B concentration, urea nitrogen, and inflammatory mediators (IL-6, TNF-α, etc.).\n\nPrimary Outcomes:\n\nClinical efficacy:\n\nTotal response rate (cure + improvement). 28-day survival rate. Time to fever resolution and bacterial clearance.\n\nDrug exposure:\n\nPolymyxin B concentration in alveolar epithelial lining fluid (ELF) and blood.\n\nSecondary Outcomes:\n\nInflammatory response: Changes in BALF and serum IL-6, TNF-α, CRP levels.\n\nSafety:\n\nNephrotoxicity (changes in serum creatinine\u002Furea nitrogen). Airway complications (bronchospasm incidence).\n\nAssessment Timeline:\n\nClinical monitoring: Daily evaluation of vital signs, sputum volume, and ventilator parameters.\n\nLab tests: Blood tests (hematology, renal function, inflammatory markers) at baseline, days 3\u002F7\u002F14.\n\nMicrobiological evaluation: Sputum cultures on days 3\u002F7\u002F14.\n\nStatistical Analysis:\n\nEfficacy and safety endpoints compared between groups using t-tests or chi-square tests.\n\nA p-value \\\u003C0.05 will be considered statistically significant.",[147,27],"Carbapenem-Resistant Enterobacteriaceae Infection","2025-07-18",{"date":150,"type":38},"2025-07-25",{"date":152,"type":38},"2023-02-01",{"date":154,"type":21},"2026-02-01",{"name":156,"class":45},"Fujian Medical University Union Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":22,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":58,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":187},"100567641","novel-tools-to-improve-management-of-paediatric-community-acquired-pneumonia---toolcap-100567641","NCT06670833","Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP","ToolCAP: Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia","ToolCAP","Inclusion Criteria:\n\n* Cough OR Difficulty Breathing AND,\n* One of the below:\n\nFast breathing (tachypnoea) \\> 50\u002Fminute (2-12 months) \\> 40\u002Fminute (1-\\\u003C5 years) \\> 25\u002Fminute (5-12 years) OR Lower chest wall indrawing\n\nExclusion Criteria:\n\n* Presenting for repeat visit\u002Ffollow-up of a treated lower respiratory tract infection (index illness \u002F non-acute) or enrolled in the study within the preceding 28 days.\n* Received antibiotic treatment for more than 48 hours at the time of enrolment.\n* WHO IMCI danger signs (inability to drink\u002Fbreastfeed, vomiting everything, convulsions with this illness, lethargy\u002Funconscious).\n* Presence of jaundice.\n* Hypoxaemia with oxygen saturation (SpO2) \\\u003C88%\n* Oxygen saturation (SpO2) \\\u003C90% (or country-specific \u002F altitude-adjusted thresholds) i) With signs of severe respiratory distress (such as nasal flaring, grunting, etc.) OR ii) In children \\\u003C 6 months\n* Requiring non-invasive ventilatory support (i.e., high-flow, bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP))\n* Underlying disease associated with increased risk of severe pneumonia or pneumonia of unusual aetiology (e.g., WHO acute malnutrition requiring antibiotics as per local guidelines, severe immunodeficiency)\n* HIV positive participant that is either i) less than 12 months old; OR ii) requires admission for this illness; OR iii) known to be uncontrolled on treatment (with a documented VL \\>1000c\u002Fml in the previous 6 months)\n* Caregiver unavailable at the time of enrolment, or unwilling, to provide informed consent.","12 Years",{"count":167,"type":21},3500,[87],"The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections. The study will also look at if it's possible to improve how doctors decide which children need antibiotics.\n\n* Lung infections are the most common reason for children to go to the clinic\u002Fhospital.\n* Doctors usually give an antibiotic to every child with a lung infection.\n* Lung infections can be caused by 2 different types of germs - bacteria or viruses.\n* Antibiotics only work against bacteria and not against viruses. Lung infections caused by viruses don't need antibiotics as the body fights them by itself.\n* Lots of research now shows that only 1 in 4 children with a lung infection actually needs an antibiotic, as the rest only have a viral infection causing the symptoms.\n* This means that 3 in 4 children get an antibiotic when they don't need it.\n* Taking too many antibiotics can cause problems for children as it can cause diseases like diabetes or asthma.\n* Nowadays, due to too many people using too many antibiotics, experts are starting to worry that bacteria are starting to become resistant (stronger than the antibiotic).\n* Ultrasound of the lungs appears to be a way of safely looking at the lungs to see if there is an infection and may help doctors better decide who needs an antibiotic.\n\nThis study includes children aged 2 months-12 years who come to the hospital with a lung infection. Children who are very unwell or who have already had 2 days of antibiotic treatment will not be allowed to be in the study.",[121,171,27,172,173,174],"Pneumonia Childhood","Pediatrics","LRTI","IMCI Guidelines",[176,177,178],"Lung ultrasound (LUS)","Lung auscultation","Pediatric pneumonia","2025-06-17",{"date":181,"type":38},"2025-06-18",{"date":183,"type":38},"2025-04-04",{"date":73,"type":21},{"name":186,"class":45},"University of Bern",9]